<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11875724</article-id><article-id pub-id-type="pmc">2375301</article-id><article-id pub-id-type="pii">6600161</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6600161</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Influence of pathological tumour variables on long-term survival in resectable gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cuschieri</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>I C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Weeden</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, UK</aff><aff id="aff2"><label>2</label>Colorectal Cancer Unit, Imperial Cancer Research Fund and Academic Department of Pathology, St Mark's Hospital, Harrow HA1 3UJ, UK</aff><aff id="aff3"><label>3</label>Cancer Division, MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:a.cuschieri@dundee.ac.uk">a.cuschieri@dundee.ac.uk</email></corresp><fn fn-type="present-address" id="note1"><p>See Acknowledgements for list of participants</p></fn></author-notes><pub-date pub-type="ppub"><day>04</day><month>03</month><year>2002</year></pub-date><volume>86</volume><issue>5</issue><fpage>674</fpage><lpage>679</lpage><history><date date-type="received"><day>01</day><month>06</month><year>2001</year></date><date date-type="rev-recd"><day>04</day><month>12</month><year>2001</year></date><date date-type="accepted"><day>28</day><month>12</month><year>2001</year></date></history><copyright-statement>Copyright 2002, Cancer Research UK</copyright-statement><copyright-year>2002</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><p>Although tumour stage and nodal status are established prognostic factors for resectable gastric cancer, the relative importance of other pathological characteristics remains unclear. This study reports univariate and multivariate analyses of the prognostic value of various pathological and staging factors based on 324 patients entered into the MRC randomised surgical trial for gastric cancer. In the univariate analysis tumour stage, nodal status, UICC clinical stage, number of involved nodes, WHO predominant type, mixed Lauren type, Ming type, tumour differentiation, lymphocytic and tumour stromal eosinophilic infiltration were all found to have a significant impact on survival (logrank test, 5&#x00025; level). In the multivariate analysis, UICC clinical stage and eosinophilic infiltration were found to have a significant influence. Risk of death increased for UICC stage II and III patients (Hazard Ratio for stage II compared to stage I&#x0003d;2.0, 95&#x00025; Confidence Interval (CI) 1.4&#x02013;2.9; Hazard Ratio for stage III compared to stage I&#x0003d;3.5, 95&#x00025; CI 2.5&#x02013;4.8). Patients with numerous eosinophils had a lower risk of death than those with none (Hazard Ratio&#x0003d;0.5, 95&#x00025; CI 0.3&#x02013;0.8). This association between survival and eosinophilic infiltration merits further study.</p><p><italic>British Journal of Cancer</italic> (2002) <bold>86</bold>, 674&#x02013;679. DOI: <ext-link ext-link-type="doi" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1038/sj/bjc/6600161">10.1038/sj/bjc/6600161</ext-link> <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.bjcancer.com">www.bjcancer.com</ext-link></p><p>&#x000a9; 2002 <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.crc.org.uk">Cancer Research UK</ext-link></p></abstract><kwd-group><kwd>gastric cancer</kwd><kwd>pathology</kwd><kwd>tumour infiltrating eosinophils</kwd><kwd>prognostic factors</kwd><kwd>survival</kwd></kwd-group></article-meta></front><body><sec><title/><p>Carcinoma of the stomach is a major cause of death within the United Kingdom. The only proven effective therapy remains surgical resection though overall 5-year survival rates remain poor. In the 1980s, results from Japan suggested that gastrectomy with radical lymphadenectomy (D<sub>2</sub> resection) improved survival over the standard D<sub>1</sub> resection (<xref ref-type="other" rid="bib22">Maruyama <italic>et al</italic>, 1987</xref>). Some Western centres practised and reported favourably on D<sub>2</sub> resections (<xref ref-type="other" rid="bib34">Sue-Ling <italic>et al</italic>, 1993</xref>) but the superiority of these operations was not tested prospectively until the launch of the Medical Research Council Gastric Cancer Surgical Trial (ST01) in 1986. In this prospective randomized study, D<sub>1</sub> resection (removal of regional perigastric nodes) was compared with D<sub>2</sub> resection (extended lymphadenectomy to include level 1 and 2 regional nodes). Central randomization followed staging laparotomy. Of 737 patients with histologically proven gastric adenocarcinoma registered, 337 were ineligible at staging laparotomy because of advanced disease and 400 were randomised.</p><p>The preliminary results of ST01 (<xref ref-type="other" rid="bib8">Cuschieri <italic>et al</italic>, 1996</xref>) and a similar Dutch trial (<xref ref-type="other" rid="bib5">Bonenkamp <italic>et al</italic>, 1995</xref>) had documented higher post-operative mortality and morbidity for patients randomised to D<sub>2</sub> resection. This was thought to be a consequence of distal pancreatectomy and splenectomy, which were an integral part of most D<sub>2</sub> procedures when these trials were designed. Long-term results of both trials have since failed to show a significant survival benefit to D<sub>2</sub> surgery (<xref ref-type="other" rid="bib6">Bonenkamp <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib9">Cuschieri <italic>et al</italic>, 1999</xref>).</p><p>An important aspect of ST01 was a full examination of all resected tumours by the pathology review panel. As well as determining tumour stage and nodal status, tumours were assessed using the WHO, Lauren, Mulligan and Ming classifications, in addition to grading based on the degree of differentiation. Extent of infiltration of the tumour stroma by lymphocytes and eosinophils was also assessed as some studies had suggested a potential survival benefit for patients with marked stromal infiltrates (<xref ref-type="other" rid="bib38">Yu <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib33">Songun <italic>et al</italic>, 1996</xref>). The effect of these pathological and staging criteria on patient survival is examined in this study.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Patients</title><p>Patients enrolled in MRC ST01 were to have had histologically proven and potentially curable gastric carcinoma. They were excluded if they were young (&#x0003c;20 years), had undergone previous gastric surgery, harboured a coexisting cancer or had serious co-morbid cardiorespiratory disease that precluded a safe D<sub>2</sub> resection. All patients underwent staging laparotomy to define potentially curative disease. Eligible cases were those that fell within the Japanese gastric cancer stages I&#x02013;III except those with positive infracolic aortic nodes. Within the same operating session patients were randomized centrally to receive either D<sub>1</sub> or D<sub>2</sub> surgery.</p></sec><sec><title>Pathology</title><p>Pathologists at each local centre provided information on the size, differentiation and extent of the tumour, and on nodal groups. In addition a panel of specialist gastrointestinal pathologists reviewed the tumours. In this analysis, all staging criteria were defined using UICC classifications (<xref ref-type="other" rid="bib32">Sobin and Wittekind, 1997</xref>). Tumour stage was assessed at pathology review. Nodal status and number of involved nodes were determined using information on nodal examination undertaken by local pathologists. These measurements were combined to give an overall clinical stage.</p><p>The review pathologists graded the tumours as well, moderately or poorly differentiated, and also assessed them using the WHO, Lauren, Mulligan and Ming classifications (<xref ref-type="other" rid="bib25">Mulligan and Rember, 1954</xref>; <xref ref-type="other" rid="bib20">Lauren, 1965</xref>; <xref ref-type="other" rid="bib23">Ming, 1977</xref>; <xref ref-type="other" rid="bib37">Watanabe <italic>et al</italic>, 1990</xref>). Eosinophilic and lymphocytic infiltration in the stroma of the tumour were also determined. The staining used for this purpose was a standard H&#x00026;E and the microscope used for the study was a Zeiss Axioplan. A &#x02018;high power field&#x02019; on this microscope (i.e., using a &#x000d7;40 objective) measures 0.6&#x02009;mm in diameter on the slide, giving an area of 1.88 mm<sup>2</sup>. The number of stromal eosinophils was recorded as &#x02018;numerous&#x02019; (an average of five or more eosinophils in 10 such high power microscopic fields (HPFs)), &#x02018;scanty&#x02019; (an average of less than five eosinophils in 10 HPFs) or &#x02018;absent&#x02019; (no eosinophils present). Stromal lymphocytic infiltration was graded as &#x02018;unremarkable&#x02019; or &#x02018;heavy infiltrate&#x02019;.</p><p>In total, 400 eligible patients were randomised into this trial. Local pathology data was collected for 386 patients. Due to logistical difficulties, only one reference pathologist (IC Talbot) was able to review the majority of the tumour slides (the other three pathologists were able to review only 8, 24 and 48&#x00025; of the material). Using Talbot's assessments (carried out blind of the clinical outcome), complete prognostic information was available for 324 patients (154 D<sub>1</sub>, 170 D<sub>2</sub>). These form the basis of the present analyses.</p><p>Patients were followed up at regular intervals. For the patients within this analysis, follow-up is available to death or 3 years in 98&#x00025; of patients and the median follow-up time is 8 years. Patients were followed up through the participating clinician, their GP or via the Office for National Statistics.</p></sec><sec><title>Statistical methods</title><p>The statistical analysis was conducted using the SPSS software system. The primary endpoint of this analysis is survival, calculated from date of surgery. The univariate survival analyses were performed using the Kaplan&#x02013;Meier method, and treatment comparisons were made via the log-rank test. Cox's proportional hazards technique was used to fit the multivariate survival model, significant prognostic factors were chosen using a forward conditional stepwise method. Categorical variables were fitted using dummy variables in the multivariate model, for ordinal variables the lowest value was used for reference. A significance level of 5&#x00025; was adopted for all analyses. No significant difference in survival between D<sub>1</sub> and D<sub>2</sub> surgery was found for this trial so it was considered reasonable to combine the treatment arms for the purposes of this analysis.</p></sec></sec><sec><title>RESULTS</title><sec><title>Patient characteristics</title><p>The main characteristics of the 324 patients included in this analysis are shown in <xref rid="tbl1" ref-type="table">Table 1</xref><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Patient characteristics at randomization</title></caption></table-wrap>. Two-thirds of the patients are male, 40&#x00025; were over 70 years old and nearly half had an antral tumour. The protocol advocated that patients in the D<sub>2</sub> arm (excepting antral tumours) should receive a distal pancreatectomy and splenectomy, which explains the imbalance in this variable. The pathological characteristics recorded by the reference pathologist, and information on staging, are displayed in <xref rid="tbl2" ref-type="table">Table 2</xref><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Survival estimates for each prognostic variable</title></caption></table-wrap>.</p></sec><sec><title>Univariate survival analysis</title><p><xref rid="tbl2" ref-type="table">Table 2</xref> contains counts and 5-year survival estimates for each level of each variable of interest. It can be seen that only Lauren predominant type and Mulligan predominant type fail to achieve significance at the 5&#x00025; level. In order to establish the combined importance of the effects of these variables, a multivariate approach was used.</p></sec><sec><title>Multivariate survival analysis</title><p>The results of the model fitting procedure can be seen in <xref rid="tbl3" ref-type="table">Table 3</xref><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Test statistics and <italic>P</italic>-values for Cox model fit</title></caption></table-wrap>. As in the univariate analysis, all of the variables except predominant Lauren type and predominant Mulligan type were significant when added into the initial model. Again clinical stage is the most important prognostic factor. When clinical stage was adjusted for, only extent of eosinophilic infiltration had a significant independent effect. Survival curves by clinical stage and eosinophil level are shown in <xref ref-type="fig" rid="fig1">Figures 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Survival by clinical staging.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="86-6600161f1"/></fig> and <xref ref-type="fig" rid="fig2">2</xref><fig id="fig2"><label>Figure 2</label><caption><p>Survival by eosinophil level.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="86-6600161f2"/></fig>.</p><p>Hazard ratios, with 95&#x00025; confidence intervals, for the significant variables are tabulated in <xref rid="tbl4" ref-type="table">Table 4</xref><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Hazard ratios for significant variables in the multivariate model</title></caption></table-wrap>. Stage II patients have double the risk of death as stage I patients, and for stage III patients the risk is increased to 3.5 times that for stage I. A high level of eosinophils was associated with less than half the risk of death of those who have no eosinophils, however it should be noted that the group of patients with a high level of eosinophils is very small. The association between improved survival and a high eosinophil count is repeated for all stages, as can be seen in <xref ref-type="fig" rid="fig3">Figure 3</xref><fig id="fig3"><label>Figure 3</label><caption><p>Survival by eosinophil level (stages I&#x02013;III).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="86-6600161f3"/></fig>.</p><p>The relationship between stromal lymphocytic and eosinophilic infiltration is shown in <xref rid="tbl5" ref-type="table">Table 5</xref><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>Eosinophilic infiltration by lymphocytic infiltration</title></caption></table-wrap>. There was no significant correlation between these variables (&#x003c7;<sup>2</sup> statistic&#x0003d;2.89, <italic>P</italic>&#x0003d;0.24 on 2 d.f.).</p><p><xref rid="tbl6" ref-type="table">Table 6</xref><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><title>Pathological classifications by clinical stage</title></caption></table-wrap> shows the pathological variables divided by clinical stage. This table gives an indication of why the significant effect of these variables detected on univariate analysis was not found in the multivariate analysis once clinical stage had been added into the model. For example, <xref rid="tbl2" ref-type="table">Table 2</xref> suggests that patients with expansive Ming type have better survival than those with infiltrative type. It can be seen in <xref rid="tbl6" ref-type="table">Table 6</xref> that 32&#x00025; of expansive patients are stage III whereas 53&#x00025; of infiltrative patients are stage III, thus ensuring lower survival for infiltrative patients. This pattern is repeated for many of the pathological variables.</p></sec></sec><sec><title>DISCUSSION</title><p>A detailed review published in 1995 (<xref ref-type="other" rid="bib14">Hermanek <italic>et al</italic>, 1995</xref>) concluded that all large multivariate studies in gastric cancer find tumour stage and nodal status to have a significant prognostic influence, but the role of other variables is less clear. Apparent differences in prognosis for different WHO or Lauren sub-types are usually explained by particular sub-types being associated with more advanced disease.</p><p>Subsequent to the review by <xref ref-type="other" rid="bib14">Hermanek <italic>et al</italic> (1995)</xref>, there have been several conflicting reports on the relationship between histological variables and survival. An Estonian study of 406 patients treated by radical gastrectomy found in a multivariate analysis that in addition to stage, nodal status, extent of gastrectomy and age; papillary, tubular and undifferentiated tumours offered better survival (<xref ref-type="other" rid="bib2">Arak and Kull, 1994</xref>). A study of 895 Spanish patients found a survival benefit for patients with intestinal Lauren type (<xref ref-type="other" rid="bib18">Jimeno-Aranda <italic>et al</italic>, 1996</xref>), although this study included stage IV patients, whereas a small Swedish study of 88 patients found a benefit for diffuse Lauren type in a univariate analysis (<xref ref-type="other" rid="bib3">Athlin <italic>et al</italic>, 1996</xref>). A population-based study of 325 patients from France reported that along with age, tumour stage, nodal status, presence of metastases, site and gross type, Ming's infiltrative type was associated with lower survival in a multivariate analysis (<xref ref-type="other" rid="bib30">Roy <italic>et al</italic>, 1998</xref>). In a Japanese series of 195 patients who received curative resection a survival benefit was demonstrated in a multivariate model for well-differentiated tumours together with number of involved nodes and depth of invasion (<xref ref-type="other" rid="bib1">Adachi <italic>et al</italic>, 1994</xref>). Well-differentiated tumours were also associated with improved survival in a study of 3926 patients from South Korea. They were included in a multivariate model with tumour stage, nodal status, gross type and location (<xref ref-type="other" rid="bib19">Kim <italic>et al</italic>, 1994</xref>).</p><p>A prospective Japanese study of 647 patients (<xref ref-type="other" rid="bib17">Iwasaki <italic>et al</italic>, 1986</xref>) found a significant difference in 5-year survival (57 <italic>vs</italic> 39&#x00025; in advanced cases) between patients with more or less than 100 eosinophils infiltrating the tumour. In the MRC study, tumour stage, nodal status, clinical stage, WHO predominant type, Lauren predominant type, Ming type, Lauren mixed type, differentiation, tumour stroma and eosinophilic infiltration were all significant at the 5&#x00025; level in the univariate analysis. However, when a multivariate survival model was chosen, only eosinophils had a significant effect once clinical stage was included in the model. Thus any apparent benefit for a particular histological subtype would appear to be explained by that subtype being associated with less advanced disease. A study based on a subset of patients entered into the Dutch gastric cancer surgical trial found on univariate analysis, that the amount of both lymphocytic and eosinophilic infiltration were of significant prognostic value (eight patients). Along with TNM stage, marked lymphocytic infiltration was also associated with better survival in multivariate analysis. However, only 105 out of 996 eligible patients were included in this analysis.</p><p>One of the difficulties of determining whether a high level of eosinophilic infiltration influences survival in gastric cancer is that the extent of eosinophil stromal infiltration has not been standardized. In the present study based on the MRC trial, as well as those described by <xref ref-type="other" rid="bib38">Yu <italic>et al</italic> (1995)</xref> and <xref ref-type="other" rid="bib33">Songun <italic>et al</italic> (1996)</xref>, eosinophil infiltration has been graded into three groups: none or few, moderate or scanty, marked or numerous. Only <xref ref-type="other" rid="bib17">Iwasaki <italic>et al</italic> (1986)</xref> described a more objective index: none, &#x0003c;100&#x02009;cells, &#x0003e;100&#x02009;cells. The subjectivity of these definitions can lead to a high level of inter-observer variation in assessments by different pathologists. This is best demonstrated by Yu's study (<xref ref-type="other" rid="bib38">Yu <italic>et al</italic>, 1995</xref>), where eosinophils graded by one pathologist had a significant effect on survival whereas the assessments of the other review pathologist were not found to be significant. We could not validly assess the inter-observer variation in the present study as only one reference pathologist examined the majority of the pathological slides. Undoubtedly this is a weakness of the present study.</p><p>Tumour stromal eosinophilic infiltration has also been documented and investigated in a study of 38 early gastric cancers (EGC). In this study electron microscopy showed tumour stromal eosinophils with morphological evidence of activation and some tumour cells in intimate contact with activated eosinophils exhibited focal cytopathic changes (<xref ref-type="other" rid="bib7">Caruso <italic>et al</italic>, 1993</xref>). Gastric carcinomas have been shown to express eosinophil chemotactic cytokines including IL-2, IL-5 and GM&#x02013;CSF and expression of GM&#x02013;CSF appears to be specific for signet ring carcinoma cells (<xref ref-type="other" rid="bib15">Hong <italic>et al</italic>, 1999</xref>).</p><p>An early report in 1983 from the Cleveland clinic on 67 colorectal carcinomas reported great variability in the number of eosinophils in histological sections of the tumours but demonstrated a positive correlation between the numbers of stromal eosinophils and survival time (<xref ref-type="other" rid="bib29">Pretlow <italic>et al</italic>, 1983</xref>). Two recent larger reports on stromal eosinophilic infiltration of colorectal cancer document a similar beneficial effect on prognosis (<xref ref-type="other" rid="bib26">Nielsen <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib11">Fernandez-Acenero <italic>et al</italic>, 2000</xref>). The improved prognosis associated with the presence of marked tumour-associated tissue eosinophilia (TATE) in two cancers at either end of the gut is interesting and merits further investigation even if this is only found in a small percentage (8&#x00025; in the present study) of these gastrointestinal cancers. Abnormal recruitment of tissue eosinophils is encountered in a variety of medical conditions including specific malignancies e.g., Hodgkin's disease certain types of leukaemia (<xref ref-type="other" rid="bib27">Ogata <italic>et al</italic>, 1998</xref>) and some solid tumours (<xref ref-type="other" rid="bib29">Pretlow <italic>et al</italic>, 1983</xref>; <xref ref-type="other" rid="bib17">Iwasaki <italic>et al</italic>, 1986</xref>; <xref ref-type="other" rid="bib4">Bethwaite <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib7">Caruso <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib38">Yu <italic>et al</italic>, 1995</xref>; <xref ref-type="other" rid="bib21">Leighton <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib33">Songun <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib28">Ono <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib13">Geisinger <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib35">Tajima <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib15">Hong <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib26">Nielsen <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib24">Moezzi <italic>et al</italic>, 2000</xref>). TATE may simply be a surrogate marker of a distinctive cytokine response to an infiltrative tumour. Alternatively TATE may indicate an unusual anti-tumour immune response. Th1 and Th2 reactions involve a variety of cell types. In general, type 1 cytokines induce a strong cellular immune response whereas type 2 cytokines, predominantly a humoral response. The two systems cross regulate each other. Type 2 cytokines (IL-4 and IL-5) are known to attract eosinophilic granulocytes and for this reason, TATE may reflect a combination of strong type 2 and weak type 1 responses (<xref ref-type="other" rid="bib36">van Driel <italic>et al</italic>, 1996</xref>). Experiments on the effector phase of tumour rejection induced by vaccination with irradiated tumour cells indicate that immunisation leads to simultaneous induction of Th1 and Th2 responses (<xref ref-type="other" rid="bib16">Hung <italic>et al</italic>, 1998</xref>). Cytokines produced by CD4(&#x0002b;) T cells activate eosinophils and macrophages and these may be responsible for direct tumour cell destruction. Tumour infiltrating eosinophils may also modulate angiogenesis and desmoplastic reaction (<xref ref-type="other" rid="bib28">Ono <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib31">Samoszuk, 1997</xref>). Eotaxin is the most researched C-C chemokine (<xref ref-type="other" rid="bib10">Fankin <italic>et al</italic>, 2000</xref>), its human gene has been characterized and shown to be an early response gene of cytokine-stimulated epithelial and endothelial cells (<xref ref-type="other" rid="bib12">Garcia-Zepeda <italic>et al</italic>, 1996</xref>). It may provide the molecular basis for eosinophil recruitment in certain tumours especially of the gastrointestinal tract.</p></sec></body><back><ack><p>This study was prepared by Simon Weeden (Medical Statistician), Alfred Cuschieri (Clinical Coordinator) and Ian Talbot (Reference Pathologist). The members of the Surgical Cooperative Group are W Allum (UK), J Bancewicz (UK), HD Becker (Germany), A Broughton (UK), FC Campbell (UK), J Clark (UK), J Craven (Jamaica), A Cuschieri (UK), A Cook (UK), I Donovan (UK), N Dorricot (UK), D Ellis (UK), J Fielding (UK), P Finan (UK), D Fossard (UK), A Hall (UK), M Hallisey (UK), T Hennessey (Ireland), D Kumar (UK), J Magnusson (Iceland), M Mughal (UK), G Sagor (UK), O Soreide (Norway), R Stedeford (UK), S Stipa (Italy), C Stoddard (UK), T Taylor (UK). The pathology reference panel consisted of I Talbot, D Levison, D Hopwood and I Filipe. The trial coordinator was Matthew Sydes and Peter Fayers was the statistician for the main trial.</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Kamakura</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Maehara</surname><given-names>Y</given-names></name><name><surname>Sugimachi</surname><given-names>K</given-names></name></person-group><article-title>Prognostic significance of the number of positive lymph nodes in gastric carcinoma</article-title><source>Br J Surg</source><year>1994</year><volume>81</volume><fpage>414</fpage><lpage>416</lpage><!--PubMed citation query: 'Br J Surg||81|414||bib1|'--><pub-id pub-id-type="pmid">8173916</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arak</surname><given-names>A</given-names></name><name><surname>Kull</surname><given-names>K</given-names></name></person-group><article-title>Factors influencing survival of patients after radical surgery for gastric cancer: a regional study of 406 patients over a 10-year period</article-title><source>Acta Oncol</source><year>1994</year><volume>33</volume><fpage>913</fpage><lpage>920</lpage><!--PubMed citation query: 'Acta Oncol||33|913||bib2|'--><pub-id pub-id-type="pmid">7818925</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Athlin</surname><given-names>L</given-names></name><name><surname>Lundskog</surname><given-names>B</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name></person-group><article-title>Local recurrence and long-term survival in patients with gastric cancer &#x02013; analysis of possible impact of clinicopathological factors</article-title><source>Eur J Surg Oncol</source><year>1996</year><volume>21</volume><fpage>162</fpage><lpage>167</lpage><!--PubMed citation query: 'Eur J Surg Oncol||21|162||bib3|'--><pub-id pub-id-type="pmid">7720891</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bethwaite</surname><given-names>PB</given-names></name><name><surname>Holloway</surname><given-names>LJ</given-names></name><name><surname>Yeong</surname><given-names>ML</given-names></name><name><surname>Thornton</surname><given-names>A</given-names></name></person-group><article-title>Effect of tumour associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix</article-title><source>J Clin Pathol</source><year>1993</year><volume>46</volume><fpage>1016</fpage><lpage>1020</lpage><!--PubMed citation query: 'J Clin Pathol||46|1016||bib4|'--><pub-id pub-id-type="pmid">8254087</pub-id></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonenkamp</surname><given-names>JJ</given-names></name><name><surname>Songun</surname><given-names>I</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>Welvaart</surname><given-names>K</given-names></name><name><surname>Plukker</surname><given-names>JTM</given-names></name><name><surname>van Elk</surname><given-names>P</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Taat</surname><given-names>CW</given-names></name><name><surname>van Lanschot</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>de Graaf</surname><given-names>PW</given-names></name><name><surname>von Meyenfeldt</surname><given-names>MF</given-names></name><name><surname>Tilanus</surname><given-names>H</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name></person-group><article-title>Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients</article-title><source>Lancet</source><year>1995</year><volume>345</volume><fpage>745</fpage><lpage>748</lpage><!--PubMed citation query: 'Lancet||345|745||bib5|'--><pub-id pub-id-type="pmid">7891484</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonenkamp</surname><given-names>JJ</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><name><surname>Sasako</surname><given-names>M</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name></person-group><article-title>Extended lymph-node dissection for gastric cancer</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>908</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||340|908||bib6|'--><pub-id pub-id-type="pmid">10089184</pub-id></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>RA</given-names></name><name><surname>Giuffre</surname><given-names>G</given-names></name><name><surname>Inferrera</surname><given-names>C</given-names></name></person-group><article-title>Minute and small early gastric carcinoma with special reference to eosinophil infiltration</article-title><source>Histol Histopathol</source><year>1993</year><volume>8</volume><fpage>155</fpage><lpage>166</lpage><!--PubMed citation query: 'Histol Histopathol||8|155||bib7|'--><pub-id pub-id-type="pmid">8443427</pub-id></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuschieri</surname><given-names>A</given-names></name><name><surname>Fayers</surname><given-names>P</given-names></name><name><surname>Fielding</surname><given-names>J</given-names></name><name><surname>Craven</surname><given-names>J</given-names></name><name><surname>Bancewicz</surname><given-names>J</given-names></name><name><surname>Joypaul</surname><given-names>V</given-names></name><name><surname>Cook</surname><given-names>P</given-names></name></person-group><article-title>Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial</article-title><source>Lancet</source><year>1996</year><volume>347</volume><fpage>995</fpage><lpage>999</lpage><!--PubMed citation query: 'Lancet||347|995||bib8|'--><pub-id pub-id-type="pmid">8606613</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuschieri</surname><given-names>A</given-names></name><name><surname>Weeden</surname><given-names>S</given-names></name><name><surname>Fielding</surname><given-names>J</given-names></name><name><surname>Bancewicz</surname><given-names>J</given-names></name><name><surname>Craven</surname><given-names>J</given-names></name><name><surname>Joypaul</surname><given-names>V</given-names></name><name><surname>Sydes</surname><given-names>M</given-names></name><name><surname>Fayers</surname><given-names>P</given-names></name></person-group><article-title>Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomised surgical trial</article-title><source>Br J Cancer</source><year>1999</year><volume>79</volume><fpage>1522</fpage><lpage>1530</lpage><!--PubMed citation query: 'Br J Cancer||79|1522||bib9|'--><pub-id pub-id-type="pmid">10188901</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fankin</surname><given-names>SM</given-names></name><name><surname>Conroy</surname><given-names>DM</given-names></name><name><surname>Williams</surname><given-names>TJ</given-names></name></person-group><article-title>Eotaxin and eosinophil recruitment: implications for human disease</article-title><source>Mol Med Today</source><year>2000</year><volume>6</volume><fpage>20</fpage><lpage>27</lpage><!--PubMed citation query: 'Mol Med Today||6|20||bib10|'--><pub-id pub-id-type="pmid">10637571</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Acenero</surname><given-names>MJ</given-names></name><name><surname>Galindo-Gallego</surname><given-names>M</given-names></name><name><surname>Sanz</surname><given-names>J</given-names></name><name><surname>Aljama</surname><given-names>A</given-names></name></person-group><article-title>Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>1544</fpage><lpage>1548</lpage><!--PubMed citation query: 'Cancer||88|1544||bib11|'--><pub-id pub-id-type="pmid">10738211</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Zepeda</surname><given-names>EA</given-names></name><name><surname>Rothenberg</surname><given-names>ME</given-names></name><name><surname>Ownbey</surname><given-names>RT</given-names></name><name><surname>Celestin</surname><given-names>J</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group><article-title>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>449</fpage><lpage>456</lpage><!--PubMed citation query: 'Nat Med||2|449||bib12|'--><pub-id pub-id-type="pmid">8597956</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geisinger</surname><given-names>KR</given-names></name><name><surname>Steffee</surname><given-names>CH</given-names></name><name><surname>McGee</surname><given-names>RS</given-names></name><name><surname>Woodruff</surname><given-names>RD</given-names></name><name><surname>Buss</surname><given-names>DH</given-names></name></person-group><article-title>The cytomorphologic features of sclerosing mucoepidermoid carcinoma of the thyroid gland with eosinophilia</article-title><source>Am J Clin Pathol</source><year>1998</year><volume>109</volume><fpage>294</fpage><lpage>301</lpage><!--PubMed citation query: 'Am J Clin Pathol||109|294||bib13|'--><pub-id pub-id-type="pmid">9495201</pub-id></citation></ref><ref id="bib14"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hermanek</surname><given-names>P</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Sobin</surname><given-names>LH</given-names></name></person-group><article-title>Stomach Carcinoma</article-title><source>Prognostic Factors in Cancer,</source><year>1995</year><publisher-name>Berlin: Springer</publisher-name><fpage>47</fpage><lpage>63</lpage>Hermanek P, Gospodarowicz MK, Henson DE, Hutter RVP, Sobin LH (eds)</citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SW</given-names></name><name><surname>Cho</surname><given-names>MY</given-names></name><name><surname>Park</surname><given-names>C</given-names></name></person-group><article-title>Expression of eosinophil chemotactic factors in stomach cancer</article-title><source>Yonsei Med J</source><year>1999</year><volume>40</volume><fpage>131</fpage><lpage>136</lpage><!--PubMed citation query: 'Yonsei Med J||40|131||bib15|'--><pub-id pub-id-type="pmid">10333716</pub-id></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>R</given-names></name><name><surname>Lafond-Walker</surname><given-names>A</given-names></name><name><surname>Lowenstein</surname><given-names>C</given-names></name><name><surname>Pardoll</surname><given-names>D</given-names></name><name><surname>Levitsky</surname><given-names>H</given-names></name></person-group><article-title>The central role of CD4(&#x0002b;) T cells in the antitumor immune response</article-title><source>J Exp Med</source><year>1998</year><volume>188</volume><fpage>2357</fpage><lpage>2368</lpage><!--PubMed citation query: 'J Exp Med||188|2357||bib16|'--><pub-id pub-id-type="pmid">9858522</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>K</given-names></name><name><surname>Torisu</surname><given-names>M</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name></person-group><article-title>Malignant tumor and eosinophils. Prognostic significance in gastric cancer</article-title><source>Cancer</source><year>1986</year><volume>58</volume><fpage>1321</fpage><lpage>1327</lpage><!--PubMed citation query: 'Cancer||58|1321||bib17|'--><pub-id pub-id-type="pmid">3742457</pub-id></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jimeno-Aranda</surname><given-names>A</given-names></name><name><surname>Sainz Samitier</surname><given-names>R</given-names></name><name><surname>Aragues</surname><given-names>GM</given-names></name></person-group><article-title>Gastric cancer in the province of Zaragoza (Spain): a survival study</article-title><source>Neoplasma</source><year>1996</year><volume>43</volume><fpage>199</fpage><lpage>203</lpage><!--PubMed citation query: 'Neoplasma||43|199||bib18|'--><pub-id pub-id-type="pmid">8841508</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JP</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><name><surname>Yang</surname><given-names>HK</given-names></name><name><surname>Noh</surname><given-names>DY</given-names></name></person-group><article-title>Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients</article-title><source>World J Surg</source><year>1994</year><volume>18</volume><fpage>872</fpage><lpage>877</lpage><!--PubMed citation query: 'World J Surg||18|872||bib19|'--><pub-id pub-id-type="pmid">7846911</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lauren</surname><given-names>P</given-names></name></person-group><article-title>The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification</article-title><source>Acta Pathol Microbiol Scand</source><year>1965</year><volume>64</volume><fpage>31</fpage><lpage>49</lpage><!--PubMed citation query: 'Acta Pathol Microbiol Scand||64|31||bib20|'--><pub-id pub-id-type="pmid">14320675</pub-id></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leighton</surname><given-names>SE</given-names></name><name><surname>Teo</surname><given-names>JG</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Cheung</surname><given-names>AY</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>van Hasselt</surname><given-names>CA</given-names></name></person-group><article-title>Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>436</fpage><lpage>440</lpage><!--PubMed citation query: 'Cancer||77|436||bib21|'--><pub-id pub-id-type="pmid">8630949</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Okabayashi</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>T</given-names></name></person-group><article-title>Progress in gastric cancer surgery and its limits of radicality</article-title><source>World J Surg</source><year>1987</year><volume>18</volume><fpage>889</fpage><lpage>895</lpage><!--PubMed citation query: 'World J Surg||18|889||bib22|'--><pub-id pub-id-type="pmid">7846914</pub-id></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ming</surname><given-names>S-C</given-names></name></person-group><article-title>Gastric carcinoma: a pathological classification</article-title><source>Cancer</source><year>1977</year><volume>39</volume><fpage>2475</fpage><lpage>2485</lpage><!--PubMed citation query: 'Cancer||39|2475||bib23|'--><pub-id pub-id-type="pmid">872047</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moezzi</surname><given-names>J</given-names></name><name><surname>Gopalswamy</surname><given-names>N</given-names></name><name><surname>Haas</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><name><surname>Markert</surname><given-names>RJ</given-names></name><name><surname>Suryaprasad</surname><given-names>S</given-names></name><name><surname>Bhutani</surname><given-names>MS</given-names></name></person-group><article-title>Stromal eosinophilia in colonic epithelial neoplasms</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>520</fpage><lpage>523</lpage><!--PubMed citation query: 'Am J Gastroenterol||95|520||bib24|'--><pub-id pub-id-type="pmid">10685761</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>RM</given-names></name><name><surname>Rember</surname><given-names>RR</given-names></name></person-group><article-title>Histogenesis and biologic behavior of gastric carcinoma: a study of 138 cases</article-title><source>Arch Pathol</source><year>1954</year><volume>58</volume><fpage>1</fpage><lpage>25</lpage><!--PubMed citation query: 'Arch Pathol||58|1||bib25|'--></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>HJ</given-names></name><name><surname>Hansen</surname><given-names>U</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><name><surname>Reimert</surname><given-names>CM</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Moesgaard</surname><given-names>F</given-names></name></person-group><article-title>Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue</article-title><source>J Pathol</source><year>1999</year><volume>189</volume><fpage>487</fpage><lpage>495</lpage><!--PubMed citation query: 'J Pathol||189|487||bib26|'--><pub-id pub-id-type="pmid">10629548</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Uno</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>E</given-names></name><name><surname>Ohtsuka</surname><given-names>E</given-names></name><name><surname>Saburi</surname><given-names>Y</given-names></name><name><surname>Kamberi</surname><given-names>P</given-names></name><name><surname>Nasu</surname><given-names>M</given-names></name><name><surname>Kikuchi</surname><given-names>H</given-names></name></person-group><article-title>Eosinophilia associated with adult T-cell leukemia: role of interleukin 5 and granulocyte-macrophage colony-stimulating factor</article-title><source>Am J Hematol</source><year>1998</year><volume>59</volume><fpage>242</fpage><lpage>245</lpage><!--PubMed citation query: 'Am J Hematol||59|242||bib27|'--><pub-id pub-id-type="pmid">9798664</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Kameyama</surname><given-names>K</given-names></name><name><surname>Otani</surname><given-names>Y</given-names></name><name><surname>Sakurai</surname><given-names>Y</given-names></name><name><surname>Kanzaki</surname><given-names>J</given-names></name></person-group><article-title>Expression of matrix metalloproteinase-1 mRNA related to eosinophilia and interleukin-5 gene expression in head and neck tumour tissue</article-title><source>Virchows Arch</source><year>1997</year><volume>431</volume><fpage>305</fpage><lpage>310</lpage><!--PubMed citation query: 'Virchows Arch||431|305||bib28|'--><pub-id pub-id-type="pmid">9463570</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pretlow</surname><given-names>TP</given-names></name><name><surname>Keith</surname><given-names>EF</given-names></name><name><surname>Cryar</surname><given-names>AK</given-names></name><name><surname>Bartolucci</surname><given-names>AA</given-names></name><name><surname>Pitts</surname><given-names>AM</given-names></name><name><surname>Pretlow</surname><given-names>TG</given-names></name><name><surname>Kimball</surname><given-names>PM</given-names></name><name><surname>Boohaker</surname><given-names>EA</given-names></name></person-group><article-title>Eosinophil infiltration of human colonic carcinomas as a prognostic indicator</article-title><source>Cancer Res</source><year>1983</year><volume>43</volume><fpage>2997</fpage><lpage>3000</lpage><!--PubMed citation query: 'Cancer Res||43|2997||bib29|'--><pub-id pub-id-type="pmid">6850611</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Piard</surname><given-names>F</given-names></name><name><surname>Dusserre-Guion</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Michiels-Marzais</surname><given-names>D</given-names></name><name><surname>Faivre</surname><given-names>J</given-names></name></person-group><article-title>Prognostic comparison of the pathological classifications of gastric cancer: a population-based study</article-title><source>Histopathology</source><year>1998</year><volume>33</volume><fpage>304</fpage><lpage>310</lpage><!--PubMed citation query: 'Histopathology||33|304||bib30|'--><pub-id pub-id-type="pmid">9822918</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Samoszuk</surname><given-names>M</given-names></name></person-group><article-title>Eosinophils and human cancer</article-title><source>Histol Histopathol</source><year>1997</year><volume>12</volume><fpage>807</fpage><lpage>812</lpage><!--PubMed citation query: 'Histol Histopathol||12|807||bib31|'--><pub-id pub-id-type="pmid">9225164</pub-id></citation></ref><ref id="bib32"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sobin</surname><given-names>LH</given-names></name><name><surname>Wittekind</surname><given-names>Ch</given-names></name></person-group><article-title/><source>TNM classification of malignant tumours</source><year>1997</year><publisher-name>New York: Wiley and Sons</publisher-name>5th Edn</citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Songun</surname><given-names>I</given-names></name><name><surname>van de Velde</surname><given-names>CJH</given-names></name><name><surname>Hermans</surname><given-names>J</given-names></name><name><surname>Pals</surname><given-names>ST</given-names></name><name><surname>Verspaget</surname><given-names>HW</given-names></name><name><surname>Vis</surname><given-names>AN</given-names></name><name><surname>Menon</surname><given-names>AG</given-names></name><name><surname>Litvinov</surname><given-names>SV</given-names></name><name><surname>van Krieken</surname><given-names>JHJM</given-names></name></person-group><article-title>Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer</article-title><source>Br J Cancer</source><year>1996</year><volume>74</volume><fpage>1783</fpage><lpage>1788</lpage><!--PubMed citation query: 'Br J Cancer||74|1783||bib33|'--><pub-id pub-id-type="pmid">8956793</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sue-Ling</surname><given-names>HM</given-names></name><name><surname>Johnston</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>IG</given-names></name><name><surname>Dixon</surname><given-names>MF</given-names></name><name><surname>Lansdown</surname><given-names>MR</given-names></name><name><surname>McMahon</surname><given-names>MJ</given-names></name><name><surname>Axon</surname><given-names>AT</given-names></name></person-group><article-title>Gastric cancer: a curable disease in Britain</article-title><source>Br Med J</source><year>1993</year><volume>307</volume><fpage>591</fpage><lpage>596</lpage><!--PubMed citation query: 'Br Med J||307|591||bib34|'--></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>K</given-names></name><name><surname>Yamakawa</surname><given-names>M</given-names></name><name><surname>Inaba</surname><given-names>Y</given-names></name><name><surname>Katagiri</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name></person-group><article-title>Cellular localization of interleukin-5 expression in rectal carcinoma with eosinophilia</article-title><source>Hum Pathol</source><year>1998</year><volume>29</volume><fpage>1024</fpage><lpage>1028</lpage><!--PubMed citation query: 'Hum Pathol||29|1024||bib35|'--><pub-id pub-id-type="pmid">9744323</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Driel</surname><given-names>WJ</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>Jansen</surname><given-names>FW</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Trimbos</surname><given-names>JB</given-names></name><name><surname>Fleuren</surname><given-names>GJ</given-names></name></person-group><article-title>Tumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune response</article-title><source>Hum Pathol</source><year>1996</year><volume>27</volume><fpage>904</fpage><lpage>911</lpage><!--PubMed citation query: 'Hum Pathol||27|904||bib36|'--><pub-id pub-id-type="pmid">8816884</pub-id></citation></ref><ref id="bib37"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Jass</surname><given-names>JR</given-names></name><name><surname>Sobin</surname><given-names>LH</given-names></name></person-group><article-title>Histological typing of oesophageal and gastric tumours</article-title><source>WHO International Histological Classification of Tumours</source><year>1990</year><publisher-name>Berlin: Springer</publisher-name>2nd edn,</citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>CC-W</given-names></name><name><surname>Levison</surname><given-names>DA</given-names></name><name><surname>Dunn</surname><given-names>JA</given-names></name><name><surname>Ward</surname><given-names>LC</given-names></name><name><surname>Demonakou</surname><given-names>M</given-names></name><name><surname>Allum</surname><given-names>WH</given-names></name><name><surname>Hallisey</surname><given-names>MT</given-names></name></person-group><article-title>Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer</article-title><source>Br J Cancer</source><year>1995</year><volume>71</volume><fpage>1106</fpage><lpage>1110</lpage><!--PubMed citation query: 'Br J Cancer||71|1106||bib38|'--><pub-id pub-id-type="pmid">7734309</pub-id></citation></ref></ref-list></back></article>


